On August 4, 2025, Dyne Therapeutics, Inc. announced that the FDA granted Breakthrough Therapy Designation to its drug DYNE-251 for treating Duchenne muscular dystrophy (DMD). This designation is significant for advancing the drug's development for patients amenable to exon 51 skipping.